World Pharma News Digest - 02.05.2012
3 views
Skip to first unread message
Ruslan David
May 2, 2012, 6:30:34 AM5/2/12
to worldph...@googlegroups.com
Serious safety concerns around unlicensed ocular bevacizumab use versus Lucentis
Recently announced results from two-year CATT[1] (Comparison of Age-related macular degeneration Treatment Trials) adds to the growing body of evidence, including CATT 1-year data and two retrospective database analyses[2],[3],[4], suggesting serious safety concerns associated with the use of unlicensed intravitreal Avastin® (bevacizumab).
Read more...
http://www.worldpharmanews.com/novartis/2062-serious-safety-concerns-around-unlicensed-ocular-bevacizumab-use-versus-lucentis
Recently announced results from two-year CATT[1] (Comparison of Age-related macular degeneration Treatment Trials) adds to the growing body of evidence, including CATT 1-year data and two retrospective database analyses[2],[3],[4], suggesting serious safety concerns associated with the use of unlicensed intravitreal Avastin® (bevacizumab).
Read more...
http://www.worldpharmanews.com/novartis/2062-serious-safety-concerns-around-unlicensed-ocular-bevacizumab-use-versus-lucentis
Pfizer reports first-quarter 2012 results
Pfizer Inc. (NYSE: PFE) today reported financial results for first-quarter 2012. First-quarter 2012 revenues were $15.4 billion, a decrease of 7% compared with $16.5 billion in the year-ago quarter, which reflects an operational decline of $1.0 billion, or 6%, and the unfavorable impact of foreign exchange of $57 million, or less than 1%.
Read more...
http://www.worldpharmanews.com/pfizer/2061-pfizer-reports-first-quarter-2012-results
Pfizer Inc. (NYSE: PFE) today reported financial results for first-quarter 2012. First-quarter 2012 revenues were $15.4 billion, a decrease of 7% compared with $16.5 billion in the year-ago quarter, which reflects an operational decline of $1.0 billion, or 6%, and the unfavorable impact of foreign exchange of $57 million, or less than 1%.
Read more...
http://www.worldpharmanews.com/pfizer/2061-pfizer-reports-first-quarter-2012-results
Stem cell researchers map new knowledge about insulin production
Scientists from The Danish Stem Cell Center (DanStem) at the University of Copenhagen and Hagedorn Research Institute have gained new insight into the signaling paths that control the body's insulin production.
Read more...
http://www.worldpharmanews.com/research/2060-stem-cell-researchers-map-new-knowledge-about-insulin-production
Scientists from The Danish Stem Cell Center (DanStem) at the University of Copenhagen and Hagedorn Research Institute have gained new insight into the signaling paths that control the body's insulin production.
Read more...
http://www.worldpharmanews.com/research/2060-stem-cell-researchers-map-new-knowledge-about-insulin-production
New drug to tackle fat problems
Medical researchers at the University of Sheffield have defined the structure of a key part of the human obesity receptor- an essential factor in the regulation of body fat- which could help provide new treatments for the complications of obesity and anorexia.
Read more...
http://www.worldpharmanews.com/research/2059-new-drug-to-tackle-fat-problems
Medical researchers at the University of Sheffield have defined the structure of a key part of the human obesity receptor- an essential factor in the regulation of body fat- which could help provide new treatments for the complications of obesity and anorexia.
Read more...
http://www.worldpharmanews.com/research/2059-new-drug-to-tackle-fat-problems
Bristol-Myers Squibb delivers a solid first quarter
Bristol-Myers Squibb Company (NYSE: BMY) announced first quarter results that included double-digit earnings growth and important R&D milestones in its metabolics and hepatitis C (HCV) franchises. The Company also confirmed guidance for 2012.
Read more...
http://www.worldpharmanews.com/bms/2058-bristol-myers-squibb-delivers-a-solid-first-quarter
Bristol-Myers Squibb Company (NYSE: BMY) announced first quarter results that included double-digit earnings growth and important R&D milestones in its metabolics and hepatitis C (HCV) franchises. The Company also confirmed guidance for 2012.
Read more...
http://www.worldpharmanews.com/bms/2058-bristol-myers-squibb-delivers-a-solid-first-quarter
Encouraging start to the year for Bayer
Sales of the Bayer Group advanced by 6.8 percent in the first quarter, to a record EUR 10,056 million (Q1 2011: EUR 9,415 million). Adjusted for currency and portfolio effects, business expanded by 5.2 percent. The operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million (Q1 2011: EUR 1,148 million).
Read more...
http://www.worldpharmanews.com/bayer/2057-encouraging-start-to-the-year-for-bayer
Sales of the Bayer Group advanced by 6.8 percent in the first quarter, to a record EUR 10,056 million (Q1 2011: EUR 9,415 million). Adjusted for currency and portfolio effects, business expanded by 5.2 percent. The operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million (Q1 2011: EUR 1,148 million).
Read more...
http://www.worldpharmanews.com/bayer/2057-encouraging-start-to-the-year-for-bayer
AstraZeneca and The Medicines Company announce global collaboration in acute ischaemic heart disease
AstraZeneca and The Medicines Company announced a global collaboration for their acute ischaemic heart disease compounds. The first part of this collaboration is a US co-promotion for AstraZeneca's oral antiplatelet medicine BRILINTA.
Read more...
http://www.worldpharmanews.com/astrazeneca/2056-astrazeneca-and-the-medicines-company-announce-global-collaboration-in-acute-ischaemic-heart-disease
AstraZeneca and The Medicines Company announced a global collaboration for their acute ischaemic heart disease compounds. The first part of this collaboration is a US co-promotion for AstraZeneca's oral antiplatelet medicine BRILINTA.
Read more...
http://www.worldpharmanews.com/astrazeneca/2056-astrazeneca-and-the-medicines-company-announce-global-collaboration-in-acute-ischaemic-heart-disease
Amgen's first quarter 2012 revenue increased 9 percent to $4.0 billion
Amgen (NASDAQ:AMGN) reported total revenue increased 9 percent during the first quarter of 2012 to $4,048 million versus $3,706 million in the first quarter of 2011. Adjusted earnings per share (EPS) were $1.61 for the first quarter of 2012, an increase of 20 percent compared to $1.34 for the first quarter of 2011.
Read more...
http://www.worldpharmanews.com/amgen/2055-amgens-first-quarter-2012-revenue-increased-9-percent-to-40-billion
Amgen (NASDAQ:AMGN) reported total revenue increased 9 percent during the first quarter of 2012 to $4,048 million versus $3,706 million in the first quarter of 2011. Adjusted earnings per share (EPS) were $1.61 for the first quarter of 2012, an increase of 20 percent compared to $1.34 for the first quarter of 2011.
Read more...
http://www.worldpharmanews.com/amgen/2055-amgens-first-quarter-2012-revenue-increased-9-percent-to-40-billion
Strong sales performance in pharmaceuticals and Alcon
Novartis net sales declined by 2% (-1% cc) to USD 13.7 billion. Currency negatively impacted sales by 1% due to the strengthening of the dollar against many currencies. Products launched since 2007 drove the Group to strong volume growth of 5 percentage points versus the previous year.
Read more...
http://www.worldpharmanews.com/novartis/2054-strong-sales-performance-in-pharmaceuticals-and-alcon
Novartis net sales declined by 2% (-1% cc) to USD 13.7 billion. Currency negatively impacted sales by 1% due to the strengthening of the dollar against many currencies. Products launched since 2007 drove the Group to strong volume growth of 5 percentage points versus the previous year.
Read more...
http://www.worldpharmanews.com/novartis/2054-strong-sales-performance-in-pharmaceuticals-and-alcon
Novo Nordisk and Oxford University team up to develop novel treatments
Today, Novo Nordisk and the Kennedy Institute of Rheumatology at Oxford University jointly announced a new partnership to develop promising new drug candidates and identify novel biomarkers and treatment targets for rheumatoid arthritis and other autoimmune inflammatory diseases.
Read more...
http://www.worldpharmanews.com/novonordisk/2053-novo-nordisk-and-oxford-university-team-up-to-develop-novel-treatments
Today, Novo Nordisk and the Kennedy Institute of Rheumatology at Oxford University jointly announced a new partnership to develop promising new drug candidates and identify novel biomarkers and treatment targets for rheumatoid arthritis and other autoimmune inflammatory diseases.
Read more...
http://www.worldpharmanews.com/novonordisk/2053-novo-nordisk-and-oxford-university-team-up-to-develop-novel-treatments
AstraZeneca to acquire Ardea Biosciences for $1 billion
AstraZeneca and Ardea Biosciences, Inc. (Ardea) have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics.
Read more...
http://www.worldpharmanews.com/astrazeneca/2052-astrazeneca-to-acquire-ardea-biosciences-for-1-billion
AstraZeneca and Ardea Biosciences, Inc. (Ardea) have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics.
Read more...
http://www.worldpharmanews.com/astrazeneca/2052-astrazeneca-to-acquire-ardea-biosciences-for-1-billion
PharmaNews.eu / Latest News
Heavy new arguments weigh in on the danger of obesity
http://www.pharmanews.eu/research-and-development/1046-heavy-new-arguments-weigh-in-on-the-danger-of-obesity
http://www.pharmanews.eu/research-and-development/1046-heavy-new-arguments-weigh-in-on-the-danger-of-obesity
Novartis drug Signifor® approved in the EU as the first medication to treat patients with Cushing's disease
http://www.pharmanews.eu/novartis/1045-novartis-drug-signiforr-approved-in-the-eu-as-the-first-medication-to-treat-patients-with-cushings-disease
http://www.pharmanews.eu/novartis/1045-novartis-drug-signiforr-approved-in-the-eu-as-the-first-medication-to-treat-patients-with-cushings-disease
'Rogue DNA' plays key role in heart failure, study shows
http://www.pharmanews.eu/research-and-development/1044-rogue-dna-plays-key-role-in-heart-failure-study-shows
http://www.pharmanews.eu/research-and-development/1044-rogue-dna-plays-key-role-in-heart-failure-study-shows
Amgen to acquire Mustafa Nevzat, a leading privately held Turkish pharmaceutical company
http://www.pharmanews.eu/amgen/1043-amgen-to-acquire-mustafa-nevzat-a-leading-privately-held-turkish-pharmaceutical-company
http://www.pharmanews.eu/amgen/1043-amgen-to-acquire-mustafa-nevzat-a-leading-privately-held-turkish-pharmaceutical-company
eSubmission Gateway now live for all applications for human medicines to the European Medicines Agency
http://www.pharmanews.eu/ema/1042-esubmission-gateway-now-live-for-all-applications-for-human-medicines-to-the-european-medicines-agency
http://www.pharmanews.eu/ema/1042-esubmission-gateway-now-live-for-all-applications-for-human-medicines-to-the-european-medicines-agency
Xenotransplantation as a therapy for type 1 diabetes
http://www.pharmanews.eu/research-and-development/1041-xenotransplantation-as-a-therapy-for-type-1-diabetes
http://www.pharmanews.eu/research-and-development/1041-xenotransplantation-as-a-therapy-for-type-1-diabetes
FORXIGA (dapagliflozin) receives positive CHMP opinion
http://www.pharmanews.eu/astrazeneca/1040-forxiga-dapagliflozin-receives-positive-chmp-opinion
http://www.pharmanews.eu/astrazeneca/1040-forxiga-dapagliflozin-receives-positive-chmp-opinion
With best regards,
Ruslan David
Administrator/Editor
Ruslan David
Administrator/Editor
PS: Want to place your News, Brand, Service, Product or Event in front of World Pharma News?
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
http://www.worldpharmanews.com/contact-us
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages